Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06133491 · ClinicalTrials.gov registry record
Open Label, 6-month Study for High Frequency and Chronic Migraine,
A clinical trial of Chronic Migraine, Headache, sponsored by Ki Health Partners..
- Active
- Registry status
- 20
- Enrollment target
- 2
- Study locations
NCT06133491: Active study of Chronic Migraine, Headache, sponsored by Ki Health Partners..
NCT06133491 is a study of Chronic Migraine, Headache that is active but no longer recruiting, run by Ki Health Partners.. The registered enrollment target is 20 participants, below the 253-participant average among 4 other Chronic Migraine, Headache trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06133491, a study of Chronic Migraine, Headache, is active but no longer recruiting, sponsored by Ki Health Partners..
- ACTIVE NOT RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs/month) requiring preventive treatment. Enrolled patients will receive DAX administered subcutaneously using an established, published, legacy injection paradigm (referred to herein as the "standard paradigm"). The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase.
Conditions Studied
Interventions
- BIOLOGICAL Daxibotulinumtonix A
Study Locations (2)
California
- The Los Angeles Headache Center - Los Angeles
Connecticut
- New England Institute for Clinical Research - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-10-18 |
| Est. Completion | 2024-12 |
What the registry record for NCT06133491 still lists
NCT06133491 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 253-participant average among 4 other Chronic Migraine, Headache trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Chronic Migraine, Headache appearing as the primary indexed condition, and to 1 intervention - of which Daxibotulinumtonix A is the first listed.
NCT06133491 reports a single indexed study location in California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06133491 about?
NCT06133491 is a clinical study titled "Open Label, 6-month Study for High Frequency and Chronic Migraine,". This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs/month) requiring preventive treatment. Enrolled patients will receive DAX administered subcutaneously using an established, published, legacy injection paradigm (referred to herein as the "standard paradigm"). T...
What is the current status of trial NCT06133491?
This trial is currently active not recruiting. The enrollment target is 20 participants. The study started on 2023-10-18. Estimated completion is 2024-12.
What conditions does trial NCT06133491 study?
This clinical trial studies the following conditions: Chronic Migraine, Headache.
What interventions are being tested in trial NCT06133491?
The interventions under investigation include: Daxibotulinumtonix A (BIOLOGICAL).
Who is sponsoring clinical trial NCT06133491?
This trial is sponsored by Ki Health Partners., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06133491 being conducted?
This trial has 2 study locations across California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Migraine, Headache
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RECRUITING
-
COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study
ACTIVE NOT RECRUITING · Phase 4
-
Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study
ACTIVE NOT RECRUITING · NA
-
Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache.
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI